FIG 3.

Swimmer plots demonstrating (A) progression-free survival (PFS) and (B) overall survival (OS) with corresponding therapy (BRAF inhibitor [BRAFi] monotherapy, BRAFi/MEK inhibitor [MEKi] combination, or MEKi monotherapy) for each patient with rare BRAF mutation included in this study. Patients with the longest PFS (> 22 months) had a V600R-, K601E-, or L597P/S-mutated melanoma (A). In general, none of the single cases achieved durable PFS. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.